Diagnosis, treatment and survival of patients with hepatorenal syndrome: a survey on daily medical practice.

[1]  R. Bellomo,et al.  Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis , 2011, Gut.

[2]  M. Pavesi,et al.  Prognostic importance of the cause of renal failure in patients with cirrhosis. , 2011, Gastroenterology.

[3]  M. Miquel,et al.  Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[4]  A. Gerbes,et al.  TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update , 2010, Gut.

[5]  V. Paradis,et al.  The spectrum of renal lesions in patients with cirrhosis: a clinicopathological study , 2010, Liver international : official journal of the International Association for the Study of the Liver.

[6]  E. Cholongitas,et al.  Terlipressin therapy for renal failure in cirrhosis , 2010, European journal of gastroenterology & hepatology.

[7]  V. Arroyo,et al.  Predictors of response to therapy with terlipressin and albumin in patients with cirrhosis and type 1 hepatorenal syndrome , 2010, Hepatology.

[8]  R. Schrier,et al.  Renal failure in cirrhosis. , 2009, The New England journal of medicine.

[9]  F. Salerno,et al.  The systemic inflammatory response syndrome in cirrhotic patients: relationship with their in-hospital outcome. , 2009, Journal of hepatology.

[10]  A. Sanyal,et al.  A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. , 2008, Gastroenterology.

[11]  V. Arroyo,et al.  Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. , 2008, Gastroenterology.

[12]  M. Malaguarnera,et al.  Terlipressin and Albumin in Patients with Cirrhosis and Type I Hepatorenal Syndrome , 2008, Digestive Diseases and Sciences.

[13]  D. Thabut,et al.  Model for end‐stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure , 2007, Hepatology.

[14]  A. Gerbes,et al.  Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis , 2007, Postgraduate Medical Journal.

[15]  E. Esrailian,et al.  Octreotide/Midodrine Therapy Significantly Improves Renal Function and 30-Day Survival in Patients with Type 1 Hepatorenal Syndrome , 2007, Digestive Diseases and Sciences.

[16]  V. Arroyo,et al.  New treatments of hepatorenal syndrome. , 2006, Seminars in liver disease.

[17]  R. MacLaren,et al.  Vasopressin, not octreotide, may be beneficial in the treatment of hepatorenal syndrome: a retrospective study. , 2005, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  F. Wong,et al.  Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome , 2004, Hepatology.

[19]  R. Bataller,et al.  Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: Results of a prospective, nonrandomized study , 2002, Hepatology.

[20]  R. Moreau,et al.  Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. , 2002, Gastroenterology.

[21]  J. Schölmerich,et al.  Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis , 1996, Hepatology.

[22]  C. Alpers,et al.  Membranoproliferative glomerulonephritis associated with hepatitis C virus infection responsive to interferon-alpha. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[23]  P. Stastny,et al.  Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. , 1971, Lancet.

[24]  N. Gitlin,et al.  Immune-complex disease of the kidney associated with chronic hepatitis and cryoglobulinaemia. , 1969, Lancet.

[25]  M. Navasa,et al.  Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. , 2004, Journal of hepatology.